Cell Signaling & Oncology

Axon Ligands™ for Cell Signaling & Oncology Research

The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].

Cell Signaling and Oncology products Library

For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.

Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.

Axon Ligands™ for Epigenetic research   Axon 5051 - Cell signaling and Oncology Library.xls                   

 

[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.

Items 1 to 15 of 21 total

per page
Page:
  1. 1
  2. 2
Axon ID Name Description From price
1810 Bortezomib Inhibitor of 26S proteasome €85.00
2935 COH000 First-in-class, highly specific, covalent allosteric inhibitor of SUMO E1 €175.00
1798 Eeyarestatin I Inhibitor of endoplasmic reticulum associated protein degradation (ERAD) €80.00
2449 LDN 57444 Reversible, competitive inhibitor of UCH-L1 deubiquitinase €95.00
1869 MG 132 Inhibitor of 26S proteasome €95.00
2309 ML 323 Selective, reversible and potent inhibitor of the USP1–UAF1 deubiquitinase complex €95.00
2995 ML 367 Inhibitor of ATAD5 stabilization €125.00
2678 ML364 Inhibitor of the deubiquitinase USP2 €125.00
2556 MLN 2238 Selective and reversible 20S proteasome inhibitor €85.00
2557 MLN 9708 Citrate prodrug of MLN 2238, selective and reversible 20S proteasome inhibitor €95.00
2565 N106 Activator of E1 ligase mediated SERCA2a SUMOylation €95.00
2228 NSC 687852 Inhibitor of 19S regulatory-particle–associated deubiquitinases (DUBs: UCHL5 and USP14) €90.00
2199 ONX 0914 Selective inhibitor of LMP7 subunit of the immunoproteasome. €95.00
2011 P 005091 Inhibitor of deubiquitinase USP7 and USP47 €95.00
1906 P 22077 Inhibitor of deubiquitinase USP7 and USP47 €95.00

Items 1 to 15 of 21 total

per page
Page:
  1. 1
  2. 2
Please wait...